NCT00503412已完成1 期
A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- The primary objective is to determine the rates & routes of excretion of 14C radiolabelled AZD2171 in patients by assessment of concentrations of total 14C radioactivity and AZD2171 in plasma & concentrations of total radioactivity in urine&faeces
研究概览
简要总结
Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed metastatic tumor which is refractory to standard therapies
- •life expectancy is 12 weeks or longer
- •WHO performance status is 0-12
排除标准
- •radiotherapy and chemotherapy within 4 weeks before the start of the study treatment
- •patients with a history of poorly controlled hypertension
- •history or evidence of any medical condition that might affect gastrointestinal function
- •patients that have participated in a radiolabelled study in the last 5 years
结局指标
主要结局
The primary objective is to determine the rates & routes of excretion of 14C radiolabelled AZD2171 in patients by assessment of concentrations of total 14C radioactivity and AZD2171 in plasma & concentrations of total radioactivity in urine&faeces
时间窗: assessed at time intervals post dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A first in man study of RGT100 injection into solid tumorsAdvanced or recurrent tumorsMedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000020962MedDRA version: 20.0Level: LLTClassification code 10024700Term: Liver metastasesSystem Organ Class: 100000020848MedDRA version: 20.0Level: LLTClassification code 10024717Term: Liver tumorSystem Organ Class: 100000020895EUCTR2016-003028-22-DERigontec GmbH15
进行中（未招募）
1 期
A first in man study of RGT100 injection into solid tumorsAdvanced or recurrent tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000020962MedDRA version: 20.0 Level: LLT Classification code 10024700 Term: Liver metastases System Organ Class: 100000020848MedDRA version: 20.0 Level: LLT Classification code 10024717 Term: Liver tumor System Organ Class: 100000020895EUCTR2016-003028-22-FRRigontec GmbH15
进行中（未招募）
1 期
A first in man study of RGT100 injection into solid tumorsAdvanced or recurrent tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000020962MedDRA version: 20.0 Level: LLT Classification code 10024700 Term: Liver metastases System Organ Class: 100000020848MedDRA version: 20.0 Level: LLT Classification code 10024717 Term: Liver tumor System Organ Class: 100000020895EUCTR2016-003028-22-GBRigontec GmbH15
进行中（未招募）
1 期
A first in man study of RGT100 injection into solid tumorsAdvanced or recurrent tumorsMedDRA version: 19.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864MedDRA version: 19.0 Level: LLT Classification code 10024700 Term: Liver metastases System Organ Class: 100000004864MedDRA version: 19.0 Level: LLT Classification code 10024717 Term: Liver tumor System Organ Class: 100000004864EUCTR2016-003028-22-ESRigontec GmbH15
进行中（未招募）
1 期
DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with metastatic HER2-low advanced or Metastatic Breast CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Metastatic Breast CancerCTIS2023-505690-33-00Astrazeneca AB192